rm-493 and Body-Weight

rm-493 has been researched along with Body-Weight* in 2 studies

Reviews

1 review(s) available for rm-493 and Body-Weight

ArticleYear
Current Mechanistic and Pharmacodynamic Understanding of Melanocortin-4 Receptor Activation.
    Molecules (Basel, Switzerland), 2019, May-16, Volume: 24, Issue:10

    In this work we summarize our understanding of melanocortin 4 receptor (MC4R) pathway activation, aiming to define a safe and effective therapeutic targeting strategy for the MC4R. Delineation of cellular MC4R pathways has provided evidence for distinct MC4R signaling events characterized by unique receptor activation kinetics. While these studies remain narrow in scope, and have largely been explored with peptidic agonists, the results provide a possible correlation between distinct ligand groups and differential MC4R activation kinetics. In addition, when a set of small-molecule and peptide MC4R agonists are compared, evidence of biased signaling has been reported. The results of such mechanistic studies are discussed.

    Topics: alpha-MSH; Animals; Body Weight; Cardiovascular System; Cyclic AMP; GTP-Binding Protein alpha Subunits, Gq-G11; Humans; Kinetics; Ligands; Peptides; Primates; Protein Binding; Protein Transport; Receptor, Melanocortin, Type 4; Rodentia; Signal Transduction

2019

Other Studies

1 other study(ies) available for rm-493 and Body-Weight

ArticleYear
Aqueous remote loading of setmelanotide in poly(lactic-co-glycolic acid) microspheres for long-term obesity treatment.
    Journal of controlled release : official journal of the Controlled Release Society, 2023, Volume: 364

    Setmelanotide (Imcivree™) was developed as a daily injectable therapeutic peptide for the treatment of rare forms of syndromic obesity, such as POMC deficiency and leptin receptor deficiency. The important option of poly(lactic-co-glycolic acid) (PLGA) controlled release microspheres has become more attractive for this class of drugs upon the discovery that net positively charged peptides can be remote-loaded rapidly from aqueous peptide solution into blank microspheres at high loading and encapsulation efficiency. Here we sought to remote-load setmelanotide in PLGA microspheres and examine its potential for long-term controlled release and body weight control. The influence of PLGA microsphere porosity was investigated with respect to morphology, drug loading, and in vitro release profiles. Increased density of the microspheres inhibited the progress of encapsulation of the dicationic peptide. A diet-induced obese murine model was then used to determine the pharmacokinetic profile and to evaluate long-term efficacy of an optimal formulation. Remote loaded PLGA formulations encapsulated setmelanotide as high as ∼63% (∼6.3% w/w loading) and exhibited slow and continuous peptide release over ∼6 weeks in vitro largely independent of microsphere porosity. The obtained in vivo release pattern from deconvolution of the pharmacokinetics after subcutaneous microsphere injection was consistent with the in vitro release profile but with a lower initial burst release and overall slightly faster release rate. After a single injection of remote-loaded setmelanotide, continuous long-term inhibition of food intake and body weight control was observed over 17 and 30 days, respectively. The improvement in body weight control over drug-free microsphere vehicle-treated control groups matched the observed PK profile. This study provides the first report of long-acting release formulation for 1-month controlled release of setmelanotide and body weight control in a diet induced obese murine model, and supports the further development of long-acting treatment options for obese patients.

    Topics: alpha-MSH; Animals; Body Weight; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Glycols; Humans; Lactic Acid; Mice; Microspheres; Obesity; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer

2023